Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

Genetic Test Predicts Obesity Risk in Early Childhood
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

Articles

Eli Lilly's Once-Weekly Insulin Efsitora Alfa Shows Positive Phase 3 Results
Inequality in Clinical Trials for Diabetes Treatments: A Closer Look
Understanding Incretin Receptor Signaling Bias and Its Potential in Treating Obesity and Type 2 Diabetes
Understanding the Impact of High-Deductible Health Plans on Diabetes Complications
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
Tirzepatide and the Future of Incretin Therapies: A New Horizon in Obesity Treatment
Semaglutide's Breakthrough in Kidney Disease Management
Denmark's AI Supercomputer: A Leap Forward in Tackling Type 2 Diabetes and Obesity
Addressing Misconceptions: A Closer Look at Weight Loss Drugs and Their Role in Managing Obesity and Type 2 Diabetes
The Manufacturing Costs and Supply Chain Dynamics of Diabetes Drugs
Empowering Type 2 Diabetes Management: Dexcom's CGM Innovations and Clinical Breakthroughs
Why mRNAs Are a Good Option for Vaccines
FDA's Ongoing Evaluation of GLP-1 RAs: No Clear Link Found Between Medication and Suicidal Thoughts or Actions
Revolutionizing Diabetes and Obesity Care with AI at Novo Nordisk
Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
GLP-1 RAs and Gastroparesis (Stomach Paralysis)
GLP-1 Drugs and Suicidal Thoughts: A Comprehensive Review by Regulators
Exploring the Neuroprotective Potential of GLP-1: A New Frontier in Medical Research
Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.